Central sleep apnea (CSA) is characterized by a lack of respiratory drive during sleep, resulting in repetitive periods of insufficient ventilation and compromised gas exchange. These nighttime breathing disturbances can lead to daytime impairment and poor cardiovascular outcomes. There are several types of CSA, including idiopathic CSA, high altitude-induced periodic breathing, obesity hypoventilation syndrome, drug-induced central apnea, and Cheyne-Stokes breathing pattern. While unstable ventilatory control during sleep is the hallmark of CSA, the pathophysiology and the prevalence of the various forms of CSA varies greatly. Among them, CSA associated with heart failure is well-studied in the respect of clinical impact and management strategy. Through this article, I will summarize the underlying pathophysiology, clinical impacts, and potential treatment of CSA occurring in subjects with heart failure.
Sleep is a natural and inevitable part of human being and the average persons spend one third of their lifetime sleeping. If sleep would not do certain vital function, it must be the greatest evolutionary mistake ever made.
However in the significant portions of adult, disorderedbreathings during sleep disrupt its normal function. 1, 2 Sleep-disordered breathing (SDB) imposes adverse impacts through sleep disruption or immediate results associated with SDB itself such as repetitive hypoxia, sympathetic over-activity, hemodynamic stress, or inflammation. 3, 4 Accumulating evidences show that SDB has a major role in the development of cardiovascular diseases. 3, 4 In this context, the effects of SDB can be more devastating in persons with underlying cardiovascular diseases such as congestive heart failure (CHF). CHF is a common condition with the estimated lifetime risk up to 20%. 5 Moreover, both obstructive and central sleep apneas are prevalent in CHF. 6 Although obstructive (OSA) and central sleep apnea (CSA) may coexist within same patient, CSA is more specifically linked to CHF. CHF is prone to the development of CSA and CSA may promote disease progression and increase mortality independent of underlying cardiac function. Therefore, main objective in this article is review the definition, pathophysiology, clinical implications, and management of CSA in CHF.
Definition and Phenotypes of Central Sleep Apnea
As the name implies, central sleep apnea and hypopnea is defined as a cessation or reduction of breathing that results from lack of or reduction in central respiratory drive.
Standard phenotyping is based on polysomnography that measures airflow and respiratory effort. Nasal pressure sensor or respiratory inductance plethysmography (RIP) is a reliable monitoring technique for airflow. 7 Although ther-LEOG, left extraoculography; REOG, right extraoculography; C3A2, C4A1, O1A2, O2A1, electrodes for electroencephalography; EMG, chin electromyography; FLWe, airflow measured by nasal pressure transducer; MicL, microphone; ECG, electrocardiography; RR, R-R interval on EKG; THO and ABD, thoracic and abdominal respiratory effort measured by strain-gauge; Body, body position; LEMG, leg electromyography; SaO2, oxygen saturation mistor or piezo-electric strain gauge is less reliable, thermistor signal is a useful reference for detecting apnea because it is very sensitive for the presence of airflow.
Operational definition of CSA is that airflow reduction is more than 90% of baseline amplitude and lasts at least 10 seconds without on-going respiratory effort (Figure 1 ). between studies. As previously described, the defining metrics of hyponea is not uniform. Researchers did or did not differentiate central hypopnea from obstructive hypopnea and adopted the varying degree of oxygen desaturation. 15, 16 Generally there is less desaturation during central apnea and hypopnea during obstructive ones in patients with CHF ( Figure 2 ). 26 Furthermore, other studies on the relationship of CSR-CSA to mortality risk have not identified whether the degree of desaturation related to apneas and hypopneas contributes mortality. [13] [14] [15] [16] [17] 27, 28 Accordingly, several studies have defined hypopneas by reductions in tidal volume or ventilation alone without any oxygen desaturation criteria.
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Pathophysiology CSR-CSA in CHF arises because of respiratory control hyperpnea. However, apnea length appears not to be affected by prolonged circulation time, but rather is proportional to the preceding decrease in PaCO2. 45, 46 Compared with patients with CSA but without CHF, patients with HF and CSR-CSA have much longer hyperpnea with more gradual increases and decreases in tidal volume, but similar apnea duration. 45 Thus, differences in the total cycle duration of periodic breathing between patients with and without CHF are primarily modulated by differences in hyperpnea, but not apnea duration.
Clinical Implications
Reported prevalence of CSA-CSR has a wide range from 15 to 37%. 6, 29, 47, 48 Earlier study before the widespread use of beta blocker for CHF therapy showed relative high prevalence because optimizing medical therapy for CHF or heart transplantation attenuates CSR-CSA. 49 These data suggest that the presence of CSR-CSA in a patient following a stroke is more likely due to underlying LV systolic dysfunction than the neurological damage caused by the stroke. They concluded that in patients with stroke, CSR-CSA is a sign of occult LV systolic dysfunction.
The main clinical significance of CSR-CSA in HF is its potential to adversely influence survival. However, there is controversy on this point. [13] [14] [15] [16] [17] 28, 54 Lanfranchi and colleagues examined 62 patients with HF and found that those with CSR-CSA had higher mortality that was proportional to the AHI than patients without CSR-CSA after controlling for confounding factors. 16 In 66 patients with HF, Sin and associates observed a 2.5-fold increased risk of death or cardiac transplantation among the 37 patients with HF with CSR-CSA than in the 29 without it after controlling for confounders. 13 Corra and coworkers found that in 133 patients with HF, an AHI greater than 30 was an independent predictor of mortality. 14 Similarly, Javaheri and colleagues found in 88 patients with HF that CSR-CSA was an independent correlate of worse survival. 15 Conversely, Andreas and coworkers did not observe increased mortality in patients with CSR-CSA during the night, but did observe an increased risk of mortality in patients presenting with CSR while awake. 27 Roebuck and colleagues followed 78 patients with severe HF being assessed for heart transplantation, of whom 42% had CSR-CSA over a median period of 52 months. 28 The presence of CSR-CSA in patients with severe HF was not significantly associated with increased mortality. CSR-CSA has been to have detrimental physiologic effects on the failing heart via sympathetic surges, hypoxia, hemodynamic stress, and so on.
Management
Given CSA patients has also been associated with an improvement of LVEF, 56 reduced mitral regurgitation, 52 and lower plasma and urinary levels of norepinephrine. 55 CPAP therapy may also reduce the number of ventricular arrhythmias, paralleling the reduction in respiratory events. 59 A small, randomized, controlled trial of 66 HF patients (with CSA, 29 patients; without CSA, 37 patients) seemed to provide further strong evidence for the efficacy of CPAP. 13 Compared with no treatment, CPAP reduced the combined mortality-cardiac transplantation rate in HF patients with CSA, but not in HF patients without CSA, over a median follow-up period of 2.2 years. 13 The CANPAP, which is the largest randomized, controlled trial published to date evaluating the efficacy of CPAP treatment for patients with CSA, was terminated early when an interim analysis suggested that a difference in transplant-free survival time between groups was unlikely to be detected. 30 At that 
